Welcome!

News Feed Item

Multiple Sclerosis Global Clinical Trials Review, H2, 2014

NEW YORK, Aug. 5, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Multiple Sclerosis Global Clinical Trials Review, H2, 2014

http://www.reportlinker.com/p02256139/Multiple-Sclerosis-Global-Clinical-Trials-Review-H2-2014.html

Multiple Sclerosis Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, "Multiple Sclerosis Global Clinical Trials Review, H2, 2014" provides data on the Multiple Sclerosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Multiple Sclerosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Multiple Sclerosis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Multiple Sclerosis 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10

Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Multiple Sclerosis to Central Nervous System Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Multiple Sclerosis to Central Nervous System Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Multiple Sclerosis 25
Subjects Recruited Over a Period of Time 35
Clinical Trials by Sponsor Type 36

Prominent Sponsors 37
Top Companies Participating in Multiple Sclerosis Therapeutics Clinical Trials 38
Prominent Drugs 40
Latest Clinical Trials News on Multiple Sclerosis 41
Jun 16, 2014: Biogen Idec and AbbVie Announce Positive Top-Line Results from Phase 3 Study Investigating Daclizumab High-Yield Process in Multiple Sclerosis 41
May 27, 2014: Bionure MS Drug Candidate Shows Positive Results for Myelin Repair in Cell Culture Assay 41
Clinical Trial Profiles 43
Clinical Trial Overview of Top Companies 43
Biogen Idec Inc. 43
Clinical Trial Overview of Biogen Idec Inc. 43
E. Merck KG 53
Clinical Trial Overview of E. Merck KG 53
Novartis AG 59
Clinical Trial Overview of Novartis AG 59
Teva Pharmaceutical Industries Limited 64
Clinical Trial Overview of Teva Pharmaceutical Industries Limited 64
Bayer AG 68
Clinical Trial Overview of Bayer AG 68

Sanofi 72
Clinical Trial Overview of Sanofi 72
GlaxoSmithKline plc 75
Clinical Trial Overview of GlaxoSmithKline plc 75
Acorda Therapeutics, Inc. 77
Clinical Trial Overview of Acorda Therapeutics, Inc. 77
Elan Corporation, plc 79
Clinical Trial Overview of Elan Corporation, plc 79
Pfizer Inc. 80
Clinical Trial Overview of Pfizer Inc. 80
Clinical Trial Overview of Top Institutes / Government 81
National Institute of Neurological Disorders and Stroke 81
Clinical Trial Overview of National Institute of Neurological Disorders and Stroke 81
Charite - Universitatsmedizin Berlin 83
Clinical Trial Overview of Charite - Universitatsmedizin Berlin 83
Tehran University of Medical Sciences 84
Clinical Trial Overview of Tehran University of Medical Sciences 84
U.S. Department of Veterans Affairs 85
Clinical Trial Overview of U.S. Department of Veterans Affairs 85
Oregon Health & Science University 86
Clinical Trial Overview of Oregon Health & Science University 86
The National Institute of Allergy and Infectious Diseases 87

Clinical Trial Overview of The National Institute of Allergy and Infectious Diseases 87
University of Washington 88
Clinical Trial Overview of University of Washington 88
St. Andrea Hospital Sapienza Rome University 89
Clinical Trial Overview of St. Andrea Hospital Sapienza Rome University 89
Imperial College London 90
Clinical Trial Overview of Imperial College London 90
Department of Health, UK 91
Clinical Trial Overview of Department of Health, UK 91
Five Key Clinical Profiles 92
Appendix 196
Abbreviations 196
Definitions 196
Research Methodology 197
Secondary Research 197
About GlobalData 198
Contact Us 198
Disclaimer 198
Source 198

List of Tables

Multiple Sclerosis Therapeutics, Global, Clinical Trials by Region, 2014* 7
Multiple Sclerosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Multiple Sclerosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Multiple Sclerosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10
Multiple Sclerosis Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Multiple Sclerosis Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Multiple Sclerosis Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2014* 13
Multiple Sclerosis Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014* 14
Proportion of Multiple Sclerosis to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 15
Multiple Sclerosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Multiple Sclerosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Multiple Sclerosis to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 18
Multiple Sclerosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Multiple Sclerosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Multiple Sclerosis Therapeutics, Global, Clinical Trials by Phase, 2014* 21

Multiple Sclerosis Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Multiple Sclerosis Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Multiple Sclerosis Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Multiple Sclerosis Therapeutics, Global, Suspended Clinical Trials, 2014* 25
Multiple Sclerosis Therapeutics, Global, Withdrawn Clinical Trials, 2014* 26
Multiple Sclerosis Therapeutics, Global, Terminated Clinical Trials, 2014* 28
Multiple Sclerosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 35
Multiple Sclerosis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 36
Multiple Sclerosis Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 37
Multiple Sclerosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 39
Multiple Sclerosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 40
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Biogen Idec Inc., 2014* 43
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by E. Merck KG, 2014* 53
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014* 59

Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Teva Pharmaceutical Industries Limited, 2014* 64
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Bayer AG, 2014* 68
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Sanofi, 2014* 72
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline plc, 2014* 75
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Acorda Therapeutics, Inc., 2014* 77
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Elan Corporation, plc, 2014* 79
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014* 80
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by National Institute of Neurological Disorders and Stroke, 2014* 81
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Charite - Universitatsmedizin Berlin, 2014* 83
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Tehran University of Medical Sciences, 2014* 84
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by U.S. Department of Veterans Affairs, 2014* 85

Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Oregon Health & Science University, 2014* 86
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by The National Institute of Allergy and Infectious Diseases, 2014* 87
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Washington, 2014* 88
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by St. Andrea Hospital Sapienza Rome University, 2014* 89
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Imperial College London, 2014* 90
Multiple Sclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Department of Health, UK, 2014* 91

List of Figures

Multiple Sclerosis Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Multiple Sclerosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Multiple Sclerosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Multiple Sclerosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 10
Multiple Sclerosis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Multiple Sclerosis Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Multiple Sclerosis Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2014* 13
Multiple Sclerosis Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014* 14
Proportion of Multiple Sclerosis to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 15
Multiple Sclerosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Multiple Sclerosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Multiple Sclerosis to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 18

Multiple Sclerosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Multiple Sclerosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Multiple Sclerosis Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Multiple Sclerosis Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Multiple Sclerosis Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Multiple Sclerosis Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Multiple Sclerosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 35
Multiple Sclerosis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 36
Multiple Sclerosis Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 37
Multiple Sclerosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 38
Multiple Sclerosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 40
GlobalData Methodology 197

To order this report: Multiple Sclerosis Global Clinical Trials Review, H2, 2014
http://www.reportlinker.com/p02256139/Multiple-Sclerosis-Global-Clinical-Trials-Review-H2-2014.html

_________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Containers are rapidly finding their way into enterprise data centers, but change is difficult. How do enterprises transform their architecture with technologies like containers without losing the reliable components of their current solutions? In his session at @DevOpsSummit at 21st Cloud Expo, Tony Campbell, Director, Educational Services at CoreOS, will explore the challenges organizations are facing today as they move to containers and go over how Kubernetes applications can deploy with lega...
SYS-CON Events announced today that Avere Systems, a leading provider of enterprise storage for the hybrid cloud, will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Avere delivers a more modern architectural approach to storage that doesn't require the overprovisioning of storage capacity to achieve performance, overspending on expensive storage media for inactive data or the overbui...
In the fast-paced advances and popularity in cloud technology, one of the most critical factors revolves around concerns for security of your critical data. How to assure both your company and your customers they can confidently trust and utilize your cloud environment is most often top on the list. There is a method to evaluating and providing security that exceeds conventional modes of protecting data both within the cloud as well externally on mobile and other devices. With the public failure...
Gemini is Yahoo’s native and search advertising platform. To ensure the quality of a complex distributed system that spans multiple products and components and across various desktop websites and mobile app and web experiences – both Yahoo owned and operated and third-party syndication (supply), with complex interaction with more than a billion users and numerous advertisers globally (demand) – it becomes imperative to automate a set of end-to-end tests 24x7 to detect bugs and regression. In th...
Today most companies are adopting or evaluating container technology - Docker in particular - to speed up application deployment, drive down cost, ease management and make application delivery more flexible overall. As with most new architectures, this dream takes significant work to become a reality. Even when you do get your application componentized enough and packaged properly, there are still challenges for DevOps teams to making the shift to continuous delivery and achieving that reducti...
As people view cloud as a preferred option to build IT systems, the size of the cloud-based system is getting bigger and more complex. As the system gets bigger, more people need to collaborate from design to management. As more people collaborate to create a bigger system, the need for a systematic approach to automate the process is required. Just as in software, cloud now needs DevOps. In this session, the audience can see how people can solve this issue with a visual model. Visual models ha...
Microsoft Azure Container Services can be used for container deployment in a variety of ways including support for Orchestrators like Kubernetes, Docker Swarm and Mesos. However, the abstraction for app development that support application self-healing, scaling and so on may not be at the right level. Helm and Draft makes this a lot easier. In this primarily demo-driven session at @DevOpsSummit at 21st Cloud Expo, Raghavan "Rags" Srinivas, a Cloud Solutions Architect/Evangelist at Microsoft, wi...
Nordstrom is transforming the way that they do business and the cloud is the key to enabling speed and hyper personalized customer experiences. In his session at 21st Cloud Expo, Ken Schow, VP of Engineering at Nordstrom, will discuss some of the key learnings and common pitfalls of large enterprises moving to the cloud. This includes strategies around choosing a cloud provider(s), architecture, and lessons learned. In addition, he’ll go over some of the best practices for structured team migr...
Coca-Cola’s Google powered digital signage system lays the groundwork for a more valuable connection between Coke and its customers. Digital signs pair software with high-resolution displays so that a message can be changed instantly based on what the operator wants to communicate or sell. In their Day 3 Keynote at 21st Cloud Expo, Greg Chambers, Global Group Director, Digital Innovation, Coca-Cola, and Vidya Nagarajan, a Senior Product Manager at Google, will discuss how from store operations...
SYS-CON Events announced today that IBM has been named “Diamond Sponsor” of SYS-CON's 21st Cloud Expo, which will take place on October 31 through November 2nd 2017 at the Santa Clara Convention Center in Santa Clara, California.
SYS-CON Events announced today that Ryobi Systems will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Ryobi Systems Co., Ltd., as an information service company, specialized in business support for local governments and medical industry. We are challenging to achive the precision farming with AI. For more information, visit http:...
As you move to the cloud, your network should be efficient, secure, and easy to manage. An enterprise adopting a hybrid or public cloud needs systems and tools that provide: Agility: ability to deliver applications and services faster, even in complex hybrid environments Easier manageability: enable reliable connectivity with complete oversight as the data center network evolves Greater efficiency: eliminate wasted effort while reducing errors and optimize asset utilization Security: imple...
High-velocity engineering teams are applying not only continuous delivery processes, but also lessons in experimentation from established leaders like Amazon, Netflix, and Facebook. These companies have made experimentation a foundation for their release processes, allowing them to try out major feature releases and redesigns within smaller groups before making them broadly available. In his session at 21st Cloud Expo, Brian Lucas, Senior Staff Engineer at Optimizely, will discuss how by using...
The next XaaS is CICDaaS. Why? Because CICD saves developers a huge amount of time. CD is an especially great option for projects that require multiple and frequent contributions to be integrated. But… securing CICD best practices is an emerging, essential, yet little understood practice for DevOps teams and their Cloud Service Providers. The only way to get CICD to work in a highly secure environment takes collaboration, patience and persistence. Building CICD in the cloud requires rigorous ar...
Transforming cloud-based data into a reportable format can be a very expensive, time-intensive and complex operation. As a SaaS platform with more than 30 million global users, Cornerstone OnDemand’s challenge was to create a scalable solution that would improve the time it took customers to access their user data. Our Real-Time Data Warehouse (RTDW) process vastly reduced data time-to-availability from 24 hours to just 10 minutes. In his session at 21st Cloud Expo, Mark Goldin, Chief Technolo...